Missing links in high quality diagnostics of inflammatory systemic rheumatic diseases: It is all about the patient!

Autoimmunity Highlights

Volumn 3, Issue 2, 2012, Pages 35-49

  Wiik, Allan S ^a,c   Bizzaro, Nicola ^b  

^a STATENS SERUM INSTITUT   (Denmark)

^b S Antonio Hospital   (Italy)

^c NONE   (Denmark)

Author keywords

Antinuclear antibodies; Autoimmunity; Harmonization; Laboratory diagnostics; Quality assurance; Standardization

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY;

AMBULATORY CARE; ANTIBODY SCREENING; ANTIPHOSPHOLIPID SYNDROME; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL LABORATORY; CLINICAL MEDICINE; CLINICAL PRACTICE; COMPUTER ASSISTED DIAGNOSIS; DATA PROCESSING; DERMATOMYOSITIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; EARLY DIAGNOSIS; ERYTHROCYTE SEDIMENTATION RATE; EUROPE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEALTH CARE QUALITY; HUMAN; IMMUNOHISTOCHEMISTRY; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY DIAGNOSIS; LEUKOCYTE COUNT; MEDICAL ETHICS; MIXED CONNECTIVE TISSUE DISEASE; NOMENCLATURE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; POLYMYOSITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN TARGETING; PUBLIC-PRIVATE PARTNERSHIP; RADIOIMMUNOPRECIPITATION; REFERENCE VALUE; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SCLERODERMA; SENSITIVITY AND SPECIFICITY; SJOEGREN SYNDROME; SMALL VESSEL VASCULITIS; STANDARDIZATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT;

EID: 84864484532     PISSN: 20380305     EISSN: 20383274     Source Type: Journal    
DOI: 10.1007/s13317-012-0029-0     Document Type: Review

References (65)

1. Humbel RL (1993) Detection of antinuclear antibodies by immunofluorescence, part 1. In: Maini RN, van Venrooij WJ (eds) Manual of biological markers of disease, section A2. Kluwer, Dordrecht, pp 1-16.
2. Wiik A, Høier-Madsen M, Forslid J, Charles P, Meyrowitsch (2010) Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J Autoimmun 35: 276-90.
3. Fritzler MJ, Wiik A, Fritzler ML, Barr SG (2003) The use and abuse of commercial kits used to detect autoantibodies. Arthritis Res Ther 5: 192-201.
4. Shoenfeld Y, Cervera R, Gershwin ME (2008) Diagnostic criteria in autoimmune diseases. Humana Press, Totowa.
5. Wiik AS, Gordon TP, Kavanaugh AF, Lahita RG, Reeves W, van Venrooij WJ, Wilson MR, Fritzler M, The IUIS/WHO/AF/CDC Committee for the Standardization of Autoantibodies in Rheumatic and Related Diseases (2004) Cutting edge diagnostics in rheumatology: the role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology. Arthritis Rheum (Arthritis Care Res) 51: 291-298.
6. Wiik AS (2005) Anti-nuclear autoantibodies: clinical utility for diagnosis, prognosis, monitoring, and planning of treatment strategy in systemic immunoinflammatory diseases. Scand J Rheumatol 34: 260-268.
7. Fries JF (1984) The chronic disease data bank: first principles to future directions. J Med Philos 9: 161-180.
8. Wiik AS, Fritzler MJ (2008) Laboratory tests in rheumatic disorders. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (eds) Rheumatology, 4th edn. Mosby Elsevier, Edinburg, pp 219-232.
9. Wiik A, Cervera R, Haass M, Kallenberg C, Khamashta M, Meroni PL et al (2006) European attempts to set guidelines for improving diagnostics of autoimmune rheumatic disorders. Lupus 15: 391-396.
10. Tozzoli R, Bizzaro N (2012) The clinical autoimmunologist and the laboratory autoimmunologist: the two sides of the coin. Autoimmun Rev. Epub ahead of print.
11. Bossuyt X, Louche C, Wiik A (2008) Standardisation in clinical laboratory medicine: an ethical reflection. Ann Rheum Dis 67: 1061-1063.
12. Chan EKL, Fritzler MJ, Wiik A, Andrade LEC, Reeves WH, Tincani A, Meroni PL, The IUIS/WHO/AF/CDC Committee for the Standardization of Autoantibodies in Rheumatic and Related Diseases (2006) AutoABSC. Org-Autoantibody Standardization Committee in 2006. Autoimmun Rev 6: 577-580.
13. Shoenfeld Y, Cervera R, Haass M, Kallenberg C, Khamashta M, Meroni PL, Piette J-C, Schmidt R, Wiik A (2007) EASI-The European Autoimmunity Standardisation Initiative: a new initiative that can contribute to agreed diagnostic models of diagnosing autoimmune disorders throughout. Ann N Y Acad Sci 1109: 138-144.
14. van Venrooij WJ, Charles P, Maini RN (1991) The consensus workshops for the detection of autoantibodies to intracellular antigens in rheumatic diseases. J Immunol Methods 140: 181-189.
15. Meroni PL, Schur PH (2010) ANA screening: an old test with new recommendations. Ann Rheum Dis 69: 1420-1422.
16. Kavanaugh A (2001) The utility of immunologic laboratory tests in patients with rheumatic diseases. Arthritis Rheum 44: 2221-2223.
17. Fritzler MJ (2010) The antinuclear antibody test: last or lasting gasp? Arthritis Rheum 63: 19-22.
18. Bizzaro N, Wiik A (2004) Appropriateness in antinuclear antibody testing: from clinical request to strategic laboratory practice. Clin Exp Rheumatol 22: 349-355.
19. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James J et al (2003) Development of auto-antibodies before the clinical onset of systemic lupus erythematosus. New Engl J Med 349: 1526-1533.
20. Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LEC (2011) Pattern on the antinuclear antibody HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 63: 191-200.
21. Wiik A, Lam K (2000) On the usability of extended DOORS for education and training, quality assurance and consensus formation. The EU CANTOR project HC 4003 (HC). Deliverable D09. 1, version 2. 1. The European Commission; 2001.
22. Wiik A, Charles P, Meyrowitsch J (2011) Multi-centre collaboration is needed to reach a unified and strictly defined classification of IIF HEp-2 cell staining patterns. In: Conrad K, Chan EKL, Meroni PL, Shoenfeld Y (eds) Autoantigens, autoantibodies, autoimmunity, vol 7. Pabst, Lengerich, pp 634-646.
23. Conrad K, Schössler W, Hiepe F, Fritzler MJ (2007) Autoantibodies in systemic autoimmune diseases. A diagnostic reference, 2nd edn. Pabst, Lengerich.
24. Stinton LM, Eystathioy T, Selak S, Chan EK, Fritzler MJ (2004) Autoantibodies to protein transport and messenger RNA processing pathways: endosomes, lysosomes, Golgi complex, proteasomes, assemblyosomes, exosomes and GW bodies. Clin Immunol 110: 30-44.
25. Hiemann R, Büttner T, Krieger T, Roggenbuck D, Sack U, Conrad K (2009) Challenges of automated screening and differentiation of non-organ specific autoantibodies on HEp-2 cells. Autoimmunity Rev 9: 17-22.
26. Egerer K, Roggenbuck D, Hiemann R, Weyer MG, Büttner T, Radau B (2010) Automated evaluation of autoantibodies on human epithelial-2 cells as an approach to standardize cell-based immuno-fluorescence tests. Arthritis Res Ther 12: R40.
27. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ et al (1997) Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 40: 1601-1611.
28. Kavanaugh A, Russell T, Reveille J, Solomon DH, Homburger HA (2000) Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. Arch Pathol Lab Med 124: 71-81.
29. Fritzler MJ, Wiik A (2006) Autoantibody assays, testing, and standardization. In: Rose NR, Mackay IR (eds) The autoimmune diseases, 4th edn. Elsevier, Amsterdam, pp 1011-1022.
30. Ghirardello A, Villalta D, Morozzi G, Galeazzi M, Gerli R et al (2011) Diagnostic accuracy of currently available anti-double-stranded DNA antibody assays. An Italian multicentre study. Clin Exp Rheumatol 29: 50-56.
31. Sack U, Conrad K, Csernok E, Frank I, Hiepe GF, Krieger T, German EASI (European Autoimmunity Standardization Initiative) et al (2009) Autoantibody detection using indirect immunofluorescence on HEp-2 cells. Dtsch Med Wochenschr 134: 1278-1282.
32. Damoiseax J, Tervaert JW, Derksen R, Hamann D, Hooijkaas H, Klasen I et al (2009) Autoantibody standardization in the Netherlands. Ann N Y Acad Sci 1173: 10-14.
33. Cervera R, Plaza A (2009) Guias de pratica clinica y laboratorio. Anticuerpos y enfermedades autoimmune. Sweden Diagnostics, Barcelona.
34. Brooks RH (1994) Appropriateness: the next frontier. BMJ 308: 218-219.
35. Wiik AS (2003) Appropriateness in autoantibody testing in clinical medicine. Clin Chim Acta 333: 177-180.
36. Damoiseaux JGMC, Cohen Tervaert JW (2006) From ANA to ENA: how to proceed? Autoimmun Rev 5: 10-17.
37. Laposata M (2004) Patient-specific narrative interpretations of complex clinical laboratory evaluations: who is competent to provide them? Clin Chem 50: 471-472.
38. Shoenfeld Y, Gershwin ME, Meroni PL (2007) Autoantibodies, 2nd edn. Elsevier, Amsterdam.
39. Satoh M, Chan JY, Ross SJ, Cerebelli A, Cavazzana I, Franceschini F et al (2011) Autoantibodies to survival of motor neuron complex in patients with polymyositis: immunoprecipitation of D, E, F and G proteins without other components of small nuclear ribonucleoproteins. Arthritis Rheum 63: 1972-1978.
40. Zieve G, Fury M, Janssen EJR (1993) Analysis of autoimmune sera by immuno-precipitation of cellular RNPs. In: van Venrooij WJ, Maini RN (eds) Manual of biological markers of disease, section A7. Kluwer, Dordrecht.
41. Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M (1994) Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 37: 75-83.
42. Kuwana M, Kaburaki J, Mimori T, Kawakami Y, Tojo T (2000) Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis. Arthritis Rheum 43: 1074-1084.
43. Mierau R, Moinzadeh P, Riemekasten G, Melchers I, Reichenberger F et al (2011) Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with clinical features. Arthritis Res Ther 13: R172.
44. Walker UA, Tyndall A, Czirja'k L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Müller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M, EUSTAR et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis 66: 754-763.
45. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G et al (2008) Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 568 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 58: 3902-3912.
46. Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Sénecal J-L (2007) Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights in clinical features and outcomes. Arthritis Res Ther 9: R78.
47. Tan EM, Smolen JS, McDougal JS, Butcher BT, Conn D, Dawkins R et al (1999) A critical evaluation of enzyme immunoassays for detection of antinuclear antibodies of defined specificity I. Precision, sensitivity, and specificity. Arthritis Rheum 42: 455-464.
48. Tan EM, Smolen J, McDougal JS, Fritzler MJ, Gordon T, Hardin JA et al (2002) A critical evaluation of enzyme immunoassays for detection of antinuclear antibodies of defined specificities. II. Potential for quantitation of antibody content. J Rheumatol 29: 68-74.
49. Fritzler MJ, Wiik A, Tan EM, Smolen JS, McDougal JS, Chan EK et al (2003) A critical evaluation of enzyme immunoassay kits for detection of antinuclear antibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturer's laboratories. J Rheumatol 30: 2374-2381.
50. van der Cruyssen B, Hoffman IE, Zmierczak H, van den Berghe M, Kruithof E, de Rycke L et al (2005) Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 64: 1145-1149.
51. Klareskog L, Catrina AI, Paget S (2009) Rheumatoid arthritis. Lancet 373: 659-672.
52. van Venrooij WJ, van Beers JJ, Pruijn GJ (2011) Anti-CCP antibodies: the past, the present and the future. Nat Rev Rheumatol 7: 391-398.
53. Wiik AS, van Venrooij WJ, Pruijn GJM (2010) All you wanted to know about anti-CCP but were afraid to ask. Autoimmun Rev 10: 90-93.
54. Bizzaro N, Tonutti E, Tozzoli R, Villalta D (2007) Analytical and diagnostic characteristics of 11 2nd- and 3rd-generation immunoenzymatic methods for the detection of antibodies to citrullinated proteins. Clin Chem 53: 1527-1533.
55. ISO 15189: 2003. Medical laboratories: particular requirements for quality and competence. ISO, Geneva, 2003.
56. Bizzaro N, Tozzoli R, Tonutti E, Piazza A, Manoni F, Ghirardello A et al (1998) Variability between methods to determine ANA, anti-dsDNA and anti-ENA autoantibodies: a collaborative study with the biomedical industry. J Immunol Methods 219: 99-107.
57. Villalta D, Bizzaro N, Platzgummer S, Antico A, Tampoia M, Camogliano L et al (2005) Accuracy of semiquantitative immunoenzymatic methods in quantitation of anti-topoisomerase I (Scl-70) antibodies. Clin Rheumatol 24: 453-459.
58. Clinical and Laboratory Standards Institute (2006) Quality Assurance of Laboratory Tests for Autoantibodies to Nuclear Antigens: (1) Indirect Fluorescence Assay for Microscopy and (2) Microtiter Enzyme Immunoassay Methods; Approved Guideline, 2nd ed. CLSI document I/LA2-A2. Wayne, PA: CLSI.
59. Bayer PM, Bauerfeind S, Bienvenu J, Fabien N, Frei PC, Gildburd B (1999) Multicenter evaluation study on an new HEp2 ANA screening enzyme immune assay. J Autoimmun 13: 89-93.
60. Rondell JMM, van Gelder M, van der Leeden H, Dinkelaar RB (1999) Different strategies in the laboratory diagnosis of autoimmune disease: immunofluorescence, enzyme-linked-immunosorbent assay or both? Ann Clin Biochem 36: 189-195.
61. Tonutti E, Bassetti D, Piazza A, Visentini D, Poletto M, Bassetto F et al (2004) Diagnostic accuracy of ELISA methods as an alternative test to indirect immunofluorescence for the detection of antinuclear antibodies. Evaluation of five commercial kits. Autoimmunity 37: 171-176.
62. Forsman RW (1996) Why is the laboratory an afterthought for managed care organizations? Clin Chem 42: 813-816.
63. Tan EM (1993) International cooperative activities in the standardization of antinuclear antibodies. Manual of biological markers of disease, vol A1. Kluwer Academic Publishers, Dordrecht, pp 1-5.
64. Smolen JS, Butcher B, Fritzler MJ, Gordon T, Hardin J, Kalden JR et al (1997) Reference sera for antibuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and Western blotting. Arthritis Rheum 40: 413-418.
65. Carey RN (2006) User verification of performances for precision and trueness; approved guideline. Clinical and Laboratory Standard Institute (CLSI) document EP15-A2, 2nd edn. CLSI: ISBN 1-56238-000-0, Wayne.